Compare Amphastar Pharmaceuticals Inc (AMPH) vs Honeywell International Inc (HON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Honeywell International Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Honeywell International Inc trades at $230.11 (market cap $76.99B). The key difference: Honeywell International Inc is far larger — about 89.1× Amphastar Pharmaceuticals Inc's market cap, and Honeywell International Inc pays a 1.15% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | HON | |
|---|---|---|
Market Cap | $863.95M | $76.99B |
Sector | Health | Industrials |
52-Week High | $30.81 | $248.79 |
52-Week Low | $16.87 | $188.14 |
Enterprise Value | $1.26B | $101.79B |
Dividend Yield | — | 1.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Honeywell Technologies (HON) trades at $246.19, up 2.26% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations, and the company has completed strategic divestitures to focus on automation. Key financials show a P/E of 9.47, net income margin of 21.58%, and robust cash flow from operations of $6.41B in 2025. The stock is near its consensus price target of $320.54, indicating potential upside.
Outlook is positive due to earnings momentum and portfolio simplification, but risks include integration challenges from spinoffs and macroeconomic sensitivity. Institutional sentiment is bullish with 66.7% buy ratings. Investors should monitor execution of growth strategies in building automation and aerospace segments for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →
